Stocks · News reference

Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5

Aug 14, 2026, 8:24 PMBenzinga Newsdesk

Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 14, 2026, 8:24 PM
Checked: Aug 14, 2026, 8:24 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 5, 2026, 1:21 PMBenzinga Newsdesk
NeuroOne Medical Technologies Reports Preliminary Q4 Sales ~$3.8M , Up 38.4% YoY; Sees FY26 Sales Of ~$10.5M, Up 15.6% YoY; Includes September Purchase Order Of $4.5M
NMTC
SEC EDGAROct 5, 2026, 1:20 PMSEC EDGAR
8-K filing — NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Filed: 2026-10-05 AccNo: 0001213900-26-106677 Size: 232 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
NMTC
BenzingaSep 17, 2026, 1:08 PMBenzinga Newsdesk
NeuroOne Medical Technologies Announces Southern California Distribution Agreement For OneRF Trigeminal Nerve Ablation System; No Minimum Purchase Commitments
NMTC
BenzingaAug 27, 2026, 3:09 PMBenzinga Newsdesk
NMTC stock has given up its prior gain. NeuroOne Medical Technologies shares were trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.
NMTC